Study of Patritumab Deruxtecan Plus Pembrolizumab with Other Anticancer Agents in Participants with High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

Trial Identifier: 1022-010
Sponsor: MSD
Collaborator:
Daiichi Sankyo
Start Date: March 2025
Primary Completion Date: December 2029
Study Completion Date: December 2034
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
Protocol Plain Language Summary – English

Trial Locations

No locations posted.